Acutus Medical Archives - Page 3 of 3 - Medical Design Sourcing

Acutus Medical names new chief financial officer

Acutus Medical today announced that it appointed David Roman as chief financial officer, effective March 1.

Roman has more than 15 years of experience in the medical technology industry. Prior to joining the company, Roman served as VP of strategy and FP&A for Baxter International. He has also held numerous leadership roles at Goldman, Sachs & Co., where he led the U.S. medical technology equity research team and Morgan Stanley where he was a research analyst for the medical technology sector.

“David is an accomplished executive with a wealth of experience in healthcare, finance and strategy,” president and CEO Vince Burgess said in a news release. “His medical technology industry expertise, operational background, and depth of relationships within the investment community will strengthen our leadership team and drive the continued execution of our strategic vision.”

Gary Doherty, Acutus Medical’s current chief financial officer, will trans…

MedTech 100 roundup: Another high as stocks tick up

For the third consecutive week, stocks in the medtech industry reached heights not yet seen since the COVID-19 pandemic began.

MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 89.65 points at the end of last week (Aug. 7). Overall, medtech stocks saw a 0.72% increase from the 89.01-point total at the same time a week prior (July 31).

On Aug. 5, the index reached 90.45 points, marking its highest point since that pre-pandemic high, with the previous mid-pandemic high (90.37) coming last week.

The most recent high mark represents just a -2% dip from the Feb. 19 high point of 92.32, marking the smallest margin of decline over the past five months.

Meanwhile, the S&P 500 Index saw a 2.5% increase from July 31 to Aug. 7, and the Dow Jones Index fared even better, positng a 3.8% rise over the same period of time.

Medtech’s lowest point during the COVID-19 pandemic remains at 62.13…

Acutus Medical launches IPO on Nasdaq

Cardiac mapping technology developer Acutus Medical announced that it priced its initial public offering on the Nasdaq market.

The Carlsbad, Calif.-based company is offering 8,823,529 shares of its common stock at $18 per share, with gross proceeds expected to come in at approximately $158.8 million.

Acutus Medical’s shares are expected to begin trading today (Aug.6, 2020) under the ticker “AFIB,” while the company anticipates that the offering while close on Aug. 10, according to a news release.

In addition to the offering, Acutus granted the underwriters a 30-day option to purchase up to more than 1.3 million additional shares of common stock at the initial offering price.

J.P. Morgan and BofA Securities are acting as joint book-running managers for the offering. William Blair is also acting as book-running manager. Canaccord Genuity and BTIG are acting as co-managers.

Acutus’ AcQMap and its 3D mapping catheter won…

Acutus Medical, Biotronik ink deal

Acutus Medical and Biotronik have announced that they will collaborate on electrophysiology, mapping, ablation and accessory products across certain markets.

Under the agreement, Acutus expects to market a range of Biotronik EP ablation catheters and diagnostic/accessory products under a private label to most international markets. The companies believe they can create a secure digital network across cardiac rhythm management and electrophysiology mapping and ablation devices.

Get the full story on our sister site MassDevice.

Acutus Medical, Biotronik ink deal

Acutus Medical and Biotronik announced an alliance to collaborate on electrophysiology, mapping, ablation and accessory products across select markets.

The products involved in the collaboration center around the treatment of cardiac arrhythmias in markets that include Europe and Asia, according to a news release.

Acutus’ AcQMap system with SuperMap multi-mode mapping capabilities lies in the center of the new alliance between companies, as Acutus touts it as the only commercially available non-contact mapping system that can map stable and unstable rhythms. Those capabilities allow for electrophysiologists to see changes in conduction during a procedure, giving them a basis on which to customize therapy.

Under the agreement, Acutus expects to, under a private label, market a range of Biotronik EP ablation catheters and diagnostic/accessory products to most international markets with the goal to optimize care for arrhythmia patients with digitally-…